Please assess the completion status of the following clinical trial:

Trial Title: An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA~* Current primary diagnosis of bipolar I disorder, mania or mixed type~* Acute exacerbation of mania associated with bipolar disorder as defined by Mania Rating Scale score \>= 18~* Hospitalized no more than 7 days at time of Screening or in process of being admitted~* History of at least one prior manic or mixed episode within past 3 years, exclusive of the current episode. Prior manic or mixed episode must be separated from current episode by at least 2 months of sustained improvement~EXCLUSION CRITERIA~* History of schizophrenia or schizoaffective disorder~* Axis I (e.g., anxiety disorder), or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results~* Current manic or mixed episode is drug-induced or secondary to a medical disorder (e.g., AIDS, corticosteroids)~* Current manic or mixed episode is believed to be caused by antidepressant use (i.e., antidepressant-induced mania)~* Had first manic episode after age 60~* Has ever taken clozapine~* Has received depot neuroleptic medication within one inter-injection interval of first dose of study drug~* Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine or amphetamines~* History of active alcohol or substance dependence within past 3 months.~* History of failed treatment on adequate valproate therapy for bipolar disorder~* Has taken Depakote (DR or ER) regularly over the last 30 days~* Has serious violent, homicidal, or suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).